Overview

Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

Status:
Completed
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers to help with coronavirus infection (COVID-19).
Phase:
Early Phase 1
Details
Lead Sponsor:
MedinCell S.A
Collaborator:
MAC Clinical Research
Treatments:
Ivermectin